

# Index

- abdomen examination, 5  
 abdominal complications, 294  
   acalculous cholecystitis, 297  
   diverticulitis, 298  
   gastrointestinal haemorrhage, 295–96  
   incidence, 295  
   mesenteric ischaemia, 296  
   pancreatitis, 296–97  
   perforations, 297–98  
   prediction, 294  
   pseudo-obstruction, 297  
   risk factors, 294  
 acalculous cholecystitis, 297  
 access site complications, 26  
 ACE inhibitors, 267, 377  
 active cycle of breathing technique (ACBT), 168  
 acute aortic syndrome, 45, 347–48  
   imaging studies, 45–47  
 acute coronary syndrome, imaging studies, 45  
 acute hypercapnic respiratory failure, ECMO, 205–6  
 acute kidney injury (AKI), 119, 120, 149, 154  
   CABG patients, 314–15  
   complications, 151  
   ECMO patients, 199  
   heart transplant patients, 336  
   nutritional implications, 162  
   paediatric surgery complications, 425  
   pathogenesis, 120  
   pulmonary endarterectomy patients, 329  
 acute lower limb ischaemia, 5  
 acute rejection, lung transplant patients, 344  
 acute respiratory distress syndrome (ARDS), 250, 365  
   cell therapies, 369  
   criteria, 251  
   definition, 365  
   ECMO, 203–5, 368  
     less severe ARDS, 205  
     severe ARDS, 203–5  
   following thoracic surgery, 359–60  
   general supportive measures, 369  
   imaging studies, 54  
   incidence, 365  
   laboratory investigations, 368  
   outcomes, 365  
   pathobiology, 365–67  
     alveolar epithelial injury, 365–66  
     circulating cell role, 367  
     endothelial activation and injury, 366–67  
     injured lung repair, 367  
     ventilator associated lung injury, 367  
   pharmacotherapy, 369  
   prone positioning, 370  
   pulmonary oedema, 47  
   treatment strategies, 360  
   ventilator management, 368  
     PEEP, 368  
     protective ventilation, 368  
     recruitment manoeuvres, 368  
     ventilatory modes, 368  
 acute respiratory failure (ARF), 247  
   hypercarbic, 249–50  
     decreased tidal ventilation, 250  
     increased CO<sub>2</sub> production, 249  
     increased dead space, 250  
   hypoxaemic, 247–49  
     diffusion abnormalities, 249  
     inadequate alveolar oxygen, 247–48  
     increased venous admixture, 249  
     shunt, 249  
     ventilation and perfusion mismatch, 248–49  
   treatment, 253–54  
     ECMO, 254  
     inhaled vasodilators, 253  
     intubation and mechanical ventilation, 253  
     non-invasive positive pressure ventilation (NIPPV), 253  
     prone positioning, 253  
     restrictive fluid strategy, 254  
     supplemental oxygen, 253  
 adenosine, 353  
 admission to critical care, xix, xxi  
   alternative resources, xx  
   diagnostic and surgical-related factors, xix  
   fast-track approach, xx  
   patient related factors, xix  
   timing, xx  
 adrenaline, *see* epinephrine  
 Advanced Directive (AD), 457  
 advanced life support (ALS), 211–13  
   drugs, 213  
   modifications, 213  
   non-VT/VF arrests, 213  
   pulseless VF/VT, 212  
 age, as risk factor, xxiv  
 air leak, 360  
 airway, 213–14  
   assessment, 59, 231  
 airway emergencies, 231  
   failed airway, 232–35  
     can't intubate, can't ventilate (CICV), 233–35  
   obstruction, 231–32  
     advanced airway management, 232  
     assessment, 231  
     causes, 231  
     initial management, 232  
     postextubation, 238  
 organisational considerations, 238–39  
   equipment, 238  
   planning and preparation, 239  
   staff and training, 238  
 postextubation emergencies, 237–38  
   airway contamination, 238  
   airway obstruction, 238  
   unplanned extubation, 237–38  
 tracheostomy emergencies, 235–37  
   airway bleeding, 237  
   blocked tube, 237  
   dislodgement, 237  
 airway pressure release ventilation (APRV), 145, 368  
 albumin, 117–19  
 alpha, receptors, 123  
 alpha<sub>2</sub>-adrenoceptor agonists, 134  
 alveolar epithelial injury, 365–66  
 Alzheimer dementia, 385  
 amiodarone, 213  
 amniotic fluid embolism, 413  
 analgesia, 135  
   delirium prevention, 396  
   infusion pharmacokinetics, 130  
   lung transplant patients, 344  
   monitoring, 135  
   non-opioid analgesia, 137–39

## Index

- analgesia (*cont.*)  
 opioids, 136–37  
 planning, 135–36  
 regional analgesia, 139–40  
 thoracic surgery, 357–59
- angiography, *see* coronary angiography
- angiotensin receptor blockers (ARBs), 377
- antibiotics  
 administration in the critically ill, 95–97  
 appropriate antibiotic therapy, 95  
 catheter related bloodstream infections, 100–1  
 endocarditis management, 98–100, 280  
 extracorporeal circuits and, 97–98  
 historical background, 95  
 implanted device infection management, 98–100  
 lung transplant patients, 341–42  
 prophylaxis, 328, 337  
 resistance, 40, 102–3, 252, 282  
   infective endocarditis, 100  
   multidrug resistant organisms, 103  
 selective digestive decontamination (SDD), 281  
 susceptibility testing, 41  
 therapeutic drug monitoring, 41
- anticoagulation, 24  
 anticoagulant characteristics, 153  
 anticoagulant reversal, 114  
 bleeding complications, 307  
 cardiac ECMO patients, 198  
 chronic thromboembolic pulmonary hypertension patients, 326, 329  
 heart failure management, 378  
 heparin resistance, 403–4  
 heparin induced thrombocytopenia patients, 405  
   bivalirudin, 405  
   renal replacement therapy, 153–54  
   valve surgery patients, 321  
   ventricular assist device implantation, 186
- antiepileptic drugs (AEDs), 291–92
- antifungals, 102
- antimicrobial stewardship, 103
- antimicrobials. *See* antibiotics
- antiplatelet agents, 24  
 platelet transfusion and, 108
- antithrombin, 404
- aorta. *See also* thoracic aortic aneurysm (TAA)  
 echocardiography, 19  
 injury, 304–5  
 trauma, 349
- aortic dissection, 19, 45, 270, 347–48, 349  
 chest pain, 243  
 classification, 347  
 traumatic, 304
- aortic regurgitation, 317  
 combined valvular pathologies, 321  
 postoperative problems, 318
- hypotension, 318  
 hypovolaemia, 318  
 ventricular assist device complications, 189
- aortic stenosis, 317  
 postoperative problems, 318  
 arrhythmia, 318  
 bradycardia, 318  
 hypertension, 318  
 hypotension, 318  
 stroke, 318  
 TAVI patients, 318
- aortic surgery  
 anaesthesia, 353–54  
 conditions requiring aortic surgery, 347  
 critical care management, 349–52  
 aortic arch surgery, 350  
 ascending aorta surgery, 350  
 descending aorta surgery, 351  
 intraoperative, 350  
 monitoring, 350  
 preoperative, 349–50  
 stable patients, 350–52  
 unstable patients, 349–50
- ICU goals, 352  
 coagulopathy management, 352  
 haemodynamics, 352  
 spinal cord protection, 352
- aortic valve surgery, 317–18  
 anatomical considerations, 317  
 common ICU problems, 318  
 physiological considerations, 317–18
- APACHE score, xxv
- aprotinin, 310
- argatroban, 405, 406
- arm examination, 4
- arrhythmias, 77. *See also specific arrhythmias*  
 aortic stenosis patients, 318  
 CABG patients, 315  
 grown-up congenital heart disease, 429  
 paediatric, 420  
   cardiac surgery complications, 424  
   pregnant patients, 415  
   thoracic surgery complications, 361–62
- arterial catheters, 87–88. *See also* vascular access  
 indications, 87  
 information from the arterial waveform, 88  
 pulse pressure variation, 88
- arterial waveform, 88
- Aspergillus* infections, 102
- aspiration  
 imaging studies, 53  
 risk factors, 53
- aspirin, 321  
 CABG patients, 315
- assist-control ventilation (AC), 145
- atelectasis  
 bronchoscopy applications, 30  
 imaging studies, 52–53  
 thoracic surgery complications, 361
- atrial fibrillation, 12  
 following thoracic surgery, 361  
 mitral valve surgery patients, 320  
 prophylaxis, 362  
 risk factors, 361  
 treatment, 362
- atrial flutter, 12
- atrial septal defect, 430
- atrioventricular septal defect, 430
- audit cycle, 446
- Autoflow<sup>®</sup>, 143
- autonomy principle, 456
- AV block, 12
- AV node re-entrant tachycardia (AVNRT), 13
- AV re-entrant tachycardia (AVRT), 13
- axillary cannulation, 196
- azathioprine, 336
- Barlow's disease, 319
- basic life support (BLS), 211
- bed rest effects, 164  
 cardiovascular, 164  
 neuromuscular, 164  
 psychological, 164  
 respiratory, 164
- bedside nurse, 441–42
- Behavioural Pain Scale (BPS), 135
- beneficence, 456
- benzodiazepines, 133–34, 396
- Bernard Soulier disease, 403
- best interests, 457
- beta receptors, 123
- beta-blockers, 266, 377
- bidirectional Glenn procedure, 423
- bilirubin levels, xxv
- biphasic positive airway pressure (BIPAP), 145
- bivalirudin, 405
- bleeding, 307–8, 402. *See also* haematological disorders  
 CABG patients, 315  
 causes, 307  
 compression of structures by clot, 307  
 following thoracic surgery, 363  
 pulmonary haemorrhage, 330  
 transfusion algorithms, 308
- blood conservation, 114
- blood cultures, 39
- blood pressure. *See also* hypertension; mean arterial pressure (MAP)  
 autoregulation, 263
- blood products, 107–11  
 allogenic product administration, 308–9  
 cryoprecipitate and fibrinogen concentrate, 110

- fresh frozen plasma, 110  
 platelets, 108–10, 309  
 prothrombin complex, 110  
 recombinant FVIIa, 111  
 red blood cells, 107–8
- blood transfusion. *See also* blood products  
 algorithms, 308  
 side effects, 108  
 transfusion coagulopathy, 309
- body composition measurement, 157
- Bolam test with the Bolitho  
 amendment, 457
- bowel ischaemia, 5, 6
- brachial plexus injury, 383
- bradycardia, 213  
 aortic stenosis patients, 318  
 causes, 77–78  
 hypothermia response, 226  
 when to pace, 78
- brain injury following cardiac  
 arrest, 458–59
- brainstem death, 459
- BRiSc score, xxv
- bronchoalveolar lavage, 30
- bronchopleural fistula, 31, 360–61  
 imaging, 54
- bronchopneumonia, 53
- bronchoscopy, 28  
 complications, 35  
 contraindications, 31–32  
 indications, 28  
 atelectasis management, 30  
 haemoptysis diagnosis and  
 management, 30  
 immunocompromised patients, 30  
 intubation, 28–29  
 persistent bronchopleural fistula, 31  
 respiratory infection diagnosis in  
 ventilated patient, 29–30  
 thoracic trauma, 30–31
- physiological effects, 31
- preparation, 32–34  
 equipment, 32  
 patient, 32  
 personnel, 33  
 precautions, 34  
 ventilation and oxygenation  
 options, 34
- procedure, 35
- procedures performed, 31  
 with conscious sedation, 34  
 with general anaesthesia, 34–35
- bundle branch block, 12
- bundle of His, 317
- bundles of care, 445
- calcineurin inhibitors, 337, 343  
 side effects, 387
- calcium channel blockers, 266, 412
- calcium sensitisers, 126–27
- Candida* infections, 102
- can't intubate, can't ventilate  
 (CICV), 233–35  
 oxygen delivery techniques, 233–35  
 rescue techniques, 233
- capnography, 214, 239
- carbohydrate, 160
- cardiac arrest, 19. *See also* resuscitation  
 causes, 213  
 non-VT/VF arrests, 213  
 out-of-hospital arrest, 220  
 early percutaneous coronary  
 intervention, 224  
 family screening, 228  
 haemodynamics, 224–25  
 intensive care management, 222  
 mechanical circulatory  
 support, 226–27  
 organ donation, 227–28  
 oxygen therapy, 225  
 practical approach, 224  
 prognostic issues, 226  
 survival, 220  
 targeted temperature  
 management, 225–26  
 ventilation, 225  
 withdrawal of cardiorespiratory  
 support, 226
- persistent precipitating pathology, 222
- postcardiac arrest brain injury, 458–59
- postcardiac arrest myocardial  
 dysfunction, 221
- postcardiac arrest syndrome, 220–21
- systemic ischaemia/reperfusion  
 response, 222
- cardiac death, 459
- cardiac ECMO, 193. *See also* extracorporeal  
 membrane oxygenation (ECMO)  
 cannulation strategies, 194–96  
 axillary/subclavian cannulation, 196  
 carotid artery cannulation, 196  
 central cannulation, 196  
 femoral artery cannulation, 194–95  
 peripheral cannulation, 194
- circuit design, 194
- complications, 199
- contraindications, 194
- future directions, 199–200
- general patient management, 196–98  
 indications, 193–94  
 outcomes, 199  
 weaning, 434
- cardiac injuries, 304
- cardiac intensivists in ACTA (CIA), 465–66
- cardiac output  
 low output following paediatric cardiac  
 surgery, 420  
 mechanical ventilation effects, 147  
 monitoring, 90–91
- cardiac power output (CPO), 374
- cardiac tamponade, 17, 244  
 paediatric, 422, 424
- cardiac transplantation. *See* heart  
 transplantation
- cardioembolism, 19
- cardiogenic shock, 256, 372. *See also* shock  
 causes, 193  
 ECMO indications, 193. *See also*  
 cardiac ECMO
- imaging studies, 47–48
- neonatal, 419
- cardiopulmonary bypass (CPB), 215,  
 350, 352  
 neurological complications, 380–81  
 risk reduction, 381  
 pregnant patients, 415
- cardiorenal syndrome, 372–73
- cardiorespiratory disease symptoms, 1
- cardiothoracic imaging, 44  
 acute aortic syndrome, 45–47  
 acute coronary syndrome, 45  
 acute respiratory distress  
 syndrome, 54  
 aspiration, 53  
 atelectasis and collapse, 52–53  
 cardiogenic shock, 47–48  
 chest pain, 45  
 chest X-ray, 44  
 computed tomography, 44–45  
 pericardial tamponade, 48  
 pleural effusion, 51  
 pneumonia, 53  
 pneumothorax, 51  
 pulmonary embolus, 48  
 pulmonary oedema, 47  
 respiratory emergencies, 50  
 right ventricular failure, 48  
 surgical complications, 49–50  
 trauma and surgery associated  
 desaturation, 54  
 ultrasound, 44
- cardiothoracic trauma. *See* trauma
- cardioversion, 82  
 special considerations, 82–83
- carotid artery cannulation, 196
- catheter insertion, 86. *See also* arterial  
 catheters; central venous catheters;  
 pulmonary arterial catheter
- complications, 86  
 pregnant patients, 409
- catheter related bloodstream  
 infections, 100–1
- central line associated bloodstream  
 infections (CLABSI), 100–1, 282  
 prevention strategies, 282
- central venous catheters, 88–89. *See also*  
 vascular access
- central pressures, 89
- central venous pressure trace, 89
- CentriMag system, 181

## Index

- cerebrospinal fluid drainage, 352–53  
 Chelsea Critical Care Physical Assessment tool (CPAx), 167  
 chest compressions, 211  
 chest drainage, 357  
   complications, 74–75  
   chylothorax, 75  
   drain malposition, 74  
   heart injury, 74  
   infection, 75  
   intercostal vessel injury, 74  
   nerve injuries, 74  
   oesophageal perforation, 75  
   re-expansion of pulmonary oedema, 74  
 contraindications, 73  
 historical background, 70  
 indications, 70  
 nursing care, 73  
 procedure, 70–73  
   anatomical landmarks, 70  
   patient positioning, 71  
   preinsertion preparation, 71  
   removal of drains, 74  
   underwater seals, 73  
 chest electrodes, 7  
 chest pain, 241  
   aortic dissection, 243  
   cardiac tamponade, 244  
   differential diagnosis, 241  
   examination, 241  
   gastrointestinal causes, 245  
   history, 241  
   imaging studies, 45  
   myocardial ischaemia, 242–43  
     postpercutaneous coronary intervention, 242  
     postsurgical revascularisation, 242–43  
   myocardial rupture, 244  
   myocarditis, 244  
   pericarditis, 244  
   superior vena cava syndrome, 243  
   Takotsubo cardiomyopathy, 245  
   tension pneumothorax, 244  
   vascular air embolism, 243–44  
   wound pain and sternal dehiscence, 245  
 chest reopening, 215  
   outside the ICU, 216  
 chest wall trauma, 302  
 chest X-ray, 44  
   pregnant patients, 410  
 children. *See* paediatrics  
 cholecystitis, 245  
   acalculous, 297  
 chronic lung allograft dysfunction (CLAD), 344  
 chronic obstructive pulmonary disease (COPD), xxiv, 252–53  
   acute exacerbations, 252  
   extracorporeal carbon dioxide removal (ECCO<sub>2</sub>R), 206  
   lung transplantation, 342–43  
   management, 252, 253  
   ventilator complications, 205  
 chronic thromboembolic pulmonary hypertension (CTEPH), 273, 324  
 cerebrovascular issues, 329  
 clinical presentation, 325  
 critical care management, 326–27  
   drugs, 328  
   fluid balance, 329  
   haematology, 329  
   monitoring, 327–28  
   ventilation, 328  
 diagnosis, 325  
 medical management, 325–26  
 pathophysiology, 324  
 pulmonary endarterectomy, 326  
 residual pulmonary hypertension, 329–30  
 surgical treatment, 324  
 chylothorax, 75, 425  
 ciclosporin, 337  
 circumflex artery, 319  
 citrate anticoagulation, 153  
 clinical audit, 446  
 clinical effectiveness, 446–47  
 clinical governance, 446  
 clinical guidelines, 445  
 clinical information systems (CIS), 449  
   components of, 449–52  
   costs and benefits, 452–54  
   effects on clinical practice, 454–55  
 clonidine, 134  
*Clostridium difficile*, 39  
 coagulopathy. *See also* haemostasis  
   postoperative tests, 111–14  
   laboratory tests, 113–14  
   point-of-care testing, 114  
   preoperative screening, 111  
 cognitive decline, 385  
 colloid solutions, 116–17  
 community acquired pneumonia (CAP), 252  
 compartment syndrome, 26  
 computed tomography (CT), 44–45, 389  
   pregnant patients, 410  
 congenital heart disease, 413–14, 418–22  
   adult. *See* grown-up congenital heart disease (GUCH)  
   incidence, 418  
   presentations, 418–20  
     arrhythmias, 420  
     cardiogenic shock, 419  
     cyanosis, 418  
     heart failure and failure to thrive, 420  
     pulmonary oedema, 420  
   univentricular circulations, 422  
     initial palliation, 422  
     superior cavopulmonary connection, 423  
     total cavopulmonary connection, 423  
 consent issues, 456–58  
   best interests, 457  
   coronary angiography, 23  
   deprivation of liberty, 458  
   medical research, 461  
   patients who have capacity, 457  
   patients who lack capacity, 457  
 constrictive pericarditis, 18  
 continuous mandatory ventilation (CMV), 144  
 continuous positive airway pressure (CPAP), 145, 170  
 continuous renal replacement therapy (CRRT), 151  
   heart transplant patients, 336  
 continuous venovenous haemofiltration (CVVH), heart failure patients, 378  
 contrast complications, 26  
 contrast induced nephropathy (CIN), 23  
 coronary angiography, 22  
   complications, 25–26  
     access site complications, 26  
     contrast complications, 26  
     major adverse cardiac events (MACE), 26  
   consent, 23  
   haemostasis and postprocedural care, 24  
   historical perspective, 22  
   image acquisition, analysis and interpretation, 24  
   indications, 22  
   preprocedural assessment, 22–24  
     access site preparation, 23  
     allergy and adverse reaction history, 23  
     anticoagulation, 24  
     antiplatelet agents, 24  
     arterial access route, 22–23  
     prehydration, 23  
     premedication, 23  
 coronary artery bypass grafting (CABG), 313  
   graft occlusion prevention, 315  
   haemodynamic management, 313–14  
   patient population, 313  
   postoperative complications, 315  
     acute kidney injury, 314–15  
     myocardial infarction, 314  
     postsurgical chest pain, 242–43  
     prevention, 388  
 coronary artery disease in pregnancy, 414–15  
 corticosteroids, 280, 336  
   antenatal, 412  
 cough assist, 170  
 creatinine levels, xxiv, xxv  
 cricoid pressure, 61

- cricothyroidotomy, 63, 233  
 critical care, xix  
 Critical Care Pain Observation Tool (CPOT), 135  
 cryoprecipitate, 110  
 crystalloid solutions, 116–17, 119  
 cyanosis  
   grown-up congenital heart disease, 428  
   neonatal, 418  
   management, 419  
 cystic fibrosis, 343  
 cytomegalovirus  
   lung transplant patients, 342  
   prophylaxis in heart transplant patients, 337
- daily sedation interruption (DSI), 132  
 damping, 87  
 dashboarding, 447  
 dead space, 250  
 death  
   brainstem, 459  
   cardiac, 459  
   diagnosis of, 458  
 deep breathing exercises (DBEx), 168  
 deep venous thrombosis, 5  
   pregnant patients, 415  
 defibrillation, 82, 211. *See also* implanted cardiac devices  
   pulseless VT/VF, 212  
   special considerations, 82–83  
 delirium, 392  
   core features, 392  
   diagnosis, 397–99  
   examination, 398  
   history, 397–98  
   investigations, 398–99  
   incidence and prevalence, 393  
   mechanisms, 393  
   negative clinical consequences, 392  
   prevention strategies, 394–97  
   general non-pharmacologic interventions, 396–97  
   perioperative interventions, 395–96  
   postoperative interventions, 396  
   preoperative screening, 394–95  
   risk factors, 393  
   screening, 397  
   subtypes, 393  
   treatment, 399  
 depression, 395  
 deprivation of liberty, 458  
 desmopressin, 310–11  
 dexmedetomidine, 135  
 diagnostic imaging. *See* cardiothoracic imaging; *specific imaging techniques*  
 diaphragmatic injury, 305  
 diaphragmatic paralysis, 425  
 diarrhoea, 39  
 diazepam, 133  
 differential lung ventilation, 146–47
- difficult intubation, 28–29, 62–63  
   predictors, 59  
 diffusion abnormalities, 249  
 distributive shock, 256  
 diuretics, 267  
   heart failure management, 375  
 diverticulitis, 298  
 Do Not Attempt Resuscitation (DNAR)  
   orders, 458  
 DO<sub>2</sub>/VO<sub>2</sub> mismatch, 257  
 dobutamine, 123–24, 275  
   heart failure management, 376  
 dopamine, 125, 275  
   heart failure management, 376  
 dopexamine, 126  
 dyspnoea, 247. *See also* acute respiratory failure (ARF)  
   chronic thromboembolic pulmonary hypertension, 325  
   COPD, 252–53  
   pneumonia, 252  
   pneumothorax, 250–51  
   pulmonary oedema, 251–52
- early rehabilitation, 165  
 Early Warning Scores (EWS), 215  
 Ebstein's anomaly, 431  
 echocardiography  
   heart failure monitoring, 374  
   indications, 15–19  
   aorta, 19  
   cardiac arrest, 19  
   haemodynamic monitoring, 19  
   intracardiac masses, 19  
   intracardiac shunts, 19  
   left ventricle, 15–17  
   pericardium, 17–18  
   pulmonary embolism, 19  
   right ventricle, 17  
   trauma, 19  
   valvular heart disease, 17  
   pregnant patients, 409  
   procedural guidance, 20  
   shock patients, 258, 259–60  
   training, 465  
   transoesophageal (TOE), 15  
   transthoracic (TTE), 15, 224  
   focused scanning, 15  
 education team, 441  
 ejection fraction (EF), 16  
 electrocardiography (ECG), 7  
   12 lead ECG, 8  
   bipolar limb leads, 8  
   ECG arrangement, 8  
   precordial leads, 8  
   unipolar augmented limb leads, 8  
 axis, 11  
 calibration, 7  
 filter settings, 7  
 heart rate, 10
- limb electrodes, 7  
 precordial (chest) electrodes, 7  
 pregnant patients, 409  
 QRS axis estimation, 11  
 QRS transition, 11  
 rhythm, 10  
 waves and intervals, 9–10  
   J point, 9  
   P wave, 9  
   PR interval, 9  
   QRS complex, 9  
   QT interval, 9  
   ST segment, 9  
   T wave, 9  
   U wave, 9
- electroencephalography (EEG), 286–88  
 delirium investigation, 398  
 failure to awaken management, 389  
 seizure diagnosis, 285  
   therapeutic monitoring, 292  
 electronic medical records, 451  
 electronic test ordering, 38  
 encephalopathy, 382–83  
 endocarditis. *See* infective endocarditis  
 endotracheal intubation. *See* intubation  
 endovascular stent graft, 349  
 energy balance, 157  
 energy expenditure, 158  
 energy intake, 157  
 enhanced recovery programs, 357  
 enoxaparin, 329  
 enoximone, 377  
 enteral nutrition, 160–61  
   composition of feeds, 161  
   contraindications, 160  
   reference daily intakes, 161  
 epileptiform activity, 292  
 epinephrine, 124–25, 213, 377  
 epsilon aminocaproic acid (EACA), 309  
 ethics principles, 456  
   autonomy, 456  
   beneficence, 456  
   justice, 456  
   non-maleficence, 456
- European Association of Cardiothoracic Surgery (EACTS) guidelines, 211  
 EuroSCORE, xxiv  
 everolimus, 337  
 examination  
   abdomen, 5  
   chest pain, 241  
   conscious patient, 4–5  
   general inspection, 4  
   hands and arms, 4  
   legs, 5  
   modification for use in critical care, 1  
   neck, 4–5  
   praecordium, 5  
   pregnant patients, 409  
   unconscious patient, 5–6, 224

## Index

- exercise testing, pregnant patients, 409  
 exponentially weighted moving average (EWMA) charts, 447  
 extracorporeal carbon dioxide removal (ECCO<sub>2</sub>R), 202  
   COPD, 206  
 extracorporeal cardiopulmonary resuscitation (eCPR), 193, 218  
   ethical and legal issues, 460  
   out-of-hospital arrest management, 226  
 Extracorporeal Life Support Organisation registry, 199  
 extracorporeal membrane oxygenation (ECMO), 202, 215  
   acute respiratory failure, 254  
   cannulation configurations, 203  
   cardiac failure management. *See* cardiac ECMO  
   complications, 5  
   ethical and legal issues, 460  
   organ retrieval, 460  
   future directions, 207  
   heart transplant patients, 335  
   indications, 203–7  
     acute hypercapnic respiratory failure, 205–6  
     acute respiratory distress syndrome (ARDS), 203–5, 368  
     lung transplantation, 206  
     primary graft dysfunction (PGD), 206  
     pulmonary vascular disease, 206–7  
   lung transplant patients, 344  
   microbiological testing, 38  
     suggested testing set, 39  
   paediatric, 423–24  
   platelet transfusion, 109  
   principles, 202  
   pulmonary endarterectomy patients, 330  
   respiratory physiotherapy, 171  
   therapeutic drug monitoring, 41  
 extravascular lung water index (EVLWI), 92  
 extubation, 63–64, 237  
   controlled, 29  
   delay, 435  
   postextubation emergencies, 237–38  
     airway contamination, 238  
     airway obstruction, 238  
     unplanned extubation, 237–38  
   protocols for early extubation, 434  
   role of checklists and prompts, 435  
   screening parameters for early extubation, 434  
 factor XII deficiency, 403  
 failed ventilation, 63, 232–35  
   can't intubate, can't ventilate (CICV), 233–35  
   oxygen delivery techniques, 233–35  
   rescue techniques, 233  
 failure to thrive, 420  
 fat, 160  
 femoral artery cannulation  
   complications, 194–95  
 fentanyl, 136  
 fibrinogen, 110  
   replacement, 110  
 fibrinolysis, 309–10  
 flexible bronchoscopy. *See* bronchoscopy  
 fluid administration, 116  
   albumin, 117–19  
   colloids vs crystalloids, 116–17  
   crystalloid solutions, 119  
   fluid responsiveness, 121  
   hydroxyethyl starch (HES), 119  
   hypertonic solutions, 119  
   indications, 116  
   pathophysiology, 116  
   sepsis patients, 279  
 fluid balance management, 119–20. *See also* fluid administration  
   lung surgery patients, 120  
   pulmonary endarterectomy patients, 329  
 fluid responsiveness, 19  
   evaluation, 259  
   shock patients, 258–59  
 follow-up, 443–44  
 Fontan and Fontan-like circulations, 432  
 forced expiration technique (FET), 168  
 fresh frozen plasma, 110  
 Full Outline of UnResponsiveness (FOUR) score, 388  
 fungal infections, 102. *See also* infections  
   lung transplant patients, 342  
 G protein coupled receptors (GPCR), 123  
   mechanism of action, 123  
 Gastrointestinal Complications Score (GICS), 294–95  
 gastrointestinal haemorrhage, 295–96  
   lower GI bleed, 295–96  
   upper GI bleed, 295  
 gender, as risk factor, xxiv  
 general anaesthesia, bronchoscopy, 34–35  
 genetic testing in pregnancy, 415  
 gestational hypertension, 410  
 Glanzmann's thrombasthenia, 403  
 global end-diastolic volume index (GEDVI), 92  
 glyceryl trinitrate, 412  
 Gott shunt, 352  
 grown-up congenital heart disease (GUCH), 427  
   ICU management, 427–29  
     cyanotic patient, 428  
     failing morphological right ventricle, 429  
     general principles, 427–28  
     univentricular heart, 429  
   indications for ICU admission, 429–30  
   arrhythmias, 429  
   endocarditis, 430  
   haemoptysis, 430  
   heart failure, 429  
   surgical/postoperative  
   admissions, 430–32  
   atrial septal defect, 430  
   atrioventricular septal defect, 430  
   congenitally corrected transposition of the great arteries, 431  
   Ebstein's anomaly, 431  
   Fontan and Fontan-type circulations, 432  
   systemic-pulmonary shunt, 431  
   tetralogy of Fallot, 431  
   transposition of the great arteries, 431  
   guidelines, 445  
   Guillain-Barré syndrome (GBS), 385  
 haematological disorders, 402. *See also* bleeding  
   congenital disorders, 402–3  
     haemophilia, 402  
     inherited platelet disorders, 403  
     von Willebrand's disease, 402–3  
   heparin resistance, 403–4  
   heparin induced thrombocytopenia (HIT), 404–5  
 haemodiafiltration, 149  
 haemodialysis, 149  
 haemodynamic monitoring, 19  
 haemofiltration, 149  
 haemophilia, 402  
 haemoptysis  
   bronchoscopy applications, 30  
   grown-up congenital heart disease patients, 430  
 haemorrhage. *See* bleeding  
 haemostasis. *See also* coagulopathy  
   cardiopulmonary bypass effects, 111  
   diagnostic testing, 111  
 haemothorax, 301  
   CABG patients, 315  
 hand examination, 4  
 health care support worker, 442  
 heart block, CABG patients, 315  
 heart failure, 180, 372  
   causes, 372  
   clinical presentation, 372  
   ECMO application, 193. *See also* cardiac ECMO  
   endocarditis, 280  
   grown-up congenital heart disease, 429  
   infants, 420  
   investigations, 373  
   management, 374–75  
     drug therapy, 375–77  
     intra-aortic balloon pump, 378  
   intubation, 375  
   non-invasive ventilation, 375

- oxygenation, 375  
 treatment goals, 374  
 ultrafiltration, 378  
 monitoring, 373–74  
 ventricular assist device  
 complications, 187–88
- heart injury in chest drainage, 74  
 heart rate, 10  
 heart rhythm, 10  
 heart transplantation, 180, 333  
 complications, 334  
 acute cellular rejection, 336  
 frequency, 387  
 neurological complications, 385–87  
 prevention and risk assessment, 388  
 contraindications, 333  
 discharge from critical care unit, 337  
 patient transfer from operating room, 333  
 postoperative care, 333–37  
 airway and ventilation, 334  
 antimicrobial prophylaxis, 337  
 cardiovascular, 334–35  
 immunosuppression, 336–37  
 renal, 336  
 preoperative assessment, 333
- HeartWare HVAD, 182  
 HELLP syndrome, 411  
 heparin, 153, 310, 321. *See also*  
 anticoagulation  
 protamine effect, 310  
 resistance, 403–4
- heparin induced thrombocytopenia (HIT), 404–5  
 diagnosis, 404  
 ICU management, 406  
 laboratory testing, 404  
 management of patients for surgery, 405–6  
 antibody positive, 405  
 bivalirudin, 405  
 treatment, 405
- hepatobiliary complications, 296–97  
 acalculous cholecystitis, 297  
 pancreatitis, 296–97
- high flow nasal oxygen therapy, 147  
 high frequency nasal oxygen (HFNO), 170  
 high frequency ventilation (HFV), 146  
 high frequency oscillatory ventilation (HFOV), 368
- high thoracic epidural analgesia (HTEA), 139  
 historical perspectives, 462–63  
 history, 1  
 chest pain, 241  
 conscious patient, 1–3  
 modification for use in critical care, 1  
 pregnant patients, 409  
 unconscious patient, 3–4, 224
- Homan's sign, 5
- hydralazine, 376, 412  
 hydroxyethyl starch (HES), 119  
 hypercarbia, 249  
 hypercarbic respiratory failure, 249–50  
 decreased tidal ventilation, 250  
 increased CO<sub>2</sub> production, 249  
 increased dead space, 250
- hypertension, 263  
 acute, 265  
 aetiology, 263–64  
 aortic stenosis patients, 318  
 classification, 264  
 diagnosis, 264–65  
 management, 265–67  
 medications, 267  
 perioperative, 266–67  
 postoperative, 267  
 preoperative, 265–66  
 pathophysiology, 263–64  
 pregnant patients, 410–12  
 postpartum care, 412  
 pulmonary. *See* pulmonary hypertension
- hypertensive crisis, 270  
 hypertensive emergency, 265  
 hypertensive urgency, 265  
 hypertonic solutions, 119  
 hypertrophic cardiomyopathy, 413  
 hypoperfusion, 257. *See also* shock  
 signs of, 258
- hypoplastic left heart syndrome (HLHS), 422  
 hypotension, 257, 279. *See also* shock  
 aortic regurgitation patients, 318  
 aortic stenosis patients, 318
- hypothermia, therapeutic, 381. *See* targeted temperature management (TTM)
- hypoventilation, 247–48  
 hypovolaemia, 273  
 aortic regurgitation patients, 318
- hypovolaemic shock, 256  
 hypoxaemic respiratory failure, 247–49  
 diffusion abnormalities, 249  
 inadequate alveolar oxygen, 247–48  
 increased venous admixture, 249  
 shunt, 249  
 ventilation and perfusion mismatch, 248–49
- idiopathic pulmonary fibrosis, 343  
 iloprost, 276  
 imaging. *See* cardiothoracic imaging
- immunocompromised patients, 30  
 immunosuppression  
 lung transplantation, 343  
 pharmacological side effects, 387
- Impella device, 175–76, 182  
 implanted cardiac devices, 77. *See also*  
 ventricular assist devices (VAD)
- implantable cardioverter defibrillators (ICDs), 79
- infection, 281  
 antibiotic therapy, 98–100  
 magnet mode, 82  
 precautions when performing procedures, 80–81  
 removal, 281  
 troubleshooting, 81–82
- incentive spirometry, 168  
 indeterminate axis, 12  
 indirect calorimetry, 158, 160  
 induction agents, 337  
 infants. *See* paediatrics  
 infections, 38, 278. *See also* antibiotics;  
 microbiological testing; *specific infections*  
 central line associated bloodstream infections, 100–1, 282  
 chest drainage complications, 75  
 fungal infections, 102  
 general clinical management, 279–80  
 heart transplant patients, 387  
 prophylaxis, 337  
 implanted cardiac devices, 98–100, 281  
 lung transplant patients, 341–42  
 bacterial, 341–42  
 fungal, 342  
 viral, 342  
 mechanical circulatory support device infections, 101–2  
 recognition of, 278–79  
 screening for resistant organisms, 40  
 surgical site, 282–83  
 thoracic surgery complications, 361  
 ventricular assist devices, 188, 281
- infective endocarditis, 4, 17, 280–81  
 antibiotic therapy, 98–100, 280  
 diagnosis, 98  
 grown-up congenital heart disease patients, 430  
 patients at high risk, 98
- inferior vena cava diameter, 19  
 inflammation  
 lung, 367  
 resolution, 367  
 steroid treatment, 369
- informed consent. *See* consent issues
- infusion pharmacokinetics, 130  
 inotropic agents. *See also* *specific drugs*  
 heart failure management, 376
- intensive care, 457  
 intensive care unit acquired weakness (ICU-AW), 385  
 intermittent positive pressure ventilation (IPPV), 169  
 intermittent renal replacement therapy (IRRT), 151  
 International Liaison Committee on Resuscitation (ILCOR), 220

## Index

- intra-aortic balloon pump (IABP),  
 173–75, 335  
 alternative insertion routes, 174  
 CABG patients, 313  
 complications, 174  
 duration and weaning, 174–75  
 heart failure management, 378  
 indications, 174  
 timing, 173
- intracardiac shunts, 19
- intracranial haemorrhage, 382
- intrathoracic blood volume index (ITBVI), 92
- intravascular fluid. *See* fluid administration
- intubating laryngeal mask airway, 63
- intubation, 59–64  
 acute respiratory failure, 253  
 airway assessment, 59  
 bronchoscopy and, 34  
 bronchoscopy applications, 28–29  
 changing endotracheal tubes, 29  
 controlled extubation, 29  
 difficult, 28–29, 62–63  
 predictors, 59  
 double lumen tube placement, 29  
 extubation, 63–64  
 failed ventilation, 63  
 heart failure patients, 375  
 indications, 59  
 management of the intubated patient, 63  
 preparation, 59–61  
 drugs, 60  
 equipment, 60  
 patient, 60  
 sequence of events, 61–62  
 confirmation of correct position, 62  
 cricoid pressure, 61  
 laryngoscopy, 61  
 preoxygenation, 61  
 team, 61  
 trauma patients, 301
- invasive monitoring, 185
- inverted ratio ventilation (IRV), 145
- isoproterenol, 125
- J point, 9
- jugular venous waveform, 4
- junctional ectopic tachycardia (JET), 424
- justice, 456
- ketamine, 139
- Kussmaul's sign, 5
- labetolol, 412
- labour management, 414
- lacerations, lung, 54
- lactate levels, 257
- Lance–Adams syndrome (LAS), 290
- laryngeal view, 62
- laryngoscopy, 61
- laryngospasm, 238
- left anterior descending artery (LAD), 24
- left anterior hemiblock (LAHB), 12
- left axis deviation, 12
- left bundle branch block (LBBB), 12
- left circumflex artery (LCx), 24
- left main coronary artery (LMCA), 24
- left posterior hemiblock (LPHB), 12
- left ventricle echocardiography, 15–17
- left ventricular assist device (LVAD), 180  
 complications, 187–89  
 aortic regurgitation, 189  
 device failure, 189  
 infections, 188  
 neurological complications, 188  
 postoperative bleeding, 187  
 right heart failure, 187–88  
 thrombosis, 188  
 contraindications, 185  
 first generation, 181  
 future directions, 189–90  
 implantation risk factor  
 assessment, 184–85  
 cardiac factors, 184  
 echocardiography, 184  
 indications, 182  
 outcome, 189  
 functional status, 189  
 quality of life, 189  
 survival, 189  
 patient selection, 184  
 perioperative management during  
 implantation, 185–87  
 ICU and ward care, 186  
 preoperative planning, 185  
 VAD team, 186–87  
 self care, 187
- left ventricular diastolic dysfunction (LVDD), 17
- left ventricular dysfunction  
 as risk factor, xxiv  
 mitral valve surgery patients, 320
- left ventricular end-diastolic area (LVEDA), 20
- left ventricular outflow tract (LVOT)  
 obstruction, 17  
 velocity–time integral (VTI), 20
- left ventricular systolic function (LVSF), 15  
 ejection fraction (EF), 16  
 fractional shortening (FS), 16
- leg examination, 5
- levetiracetam, 292
- levosimendan, 126, 275  
 heart failure management, 377
- LiDCO system, 92
- lidocaine toxicity, 35
- limb electrodes, 7
- limitation of treatment, 458
- lorazepam, 134, 291
- lung collapse, imaging studies, 52–53
- lung disease as risk factor, xxiv
- lung injuries, 303
- lung rest strategy, 205
- lung torsion, postoperative, 54
- lung transplantation, 340  
 chronic obstructive pulmonary  
 disease, 342–43  
 cystic fibrosis, 343  
 drug interactions, 343  
 ECMO applications, 206, 344  
 general ICU issues, 340  
 idiopathic pulmonary fibrosis, 343  
 indications, 340  
 infections, 341–42  
 bacterial, 341–42  
 fungal, 342  
 viral, 342  
 late admissions to ICU, 344  
 mobilisation, 344–45  
 primary graft dysfunction, 340–41  
 pulmonary hypertension, 343  
 lysine analogues, 309–10
- macrocirculation, 256
- macronutrients, 160  
 carbohydrate, 160  
 fat, 160  
 protein, 160
- magnesium sulphate, 412  
 toxicity, 412
- magnetic resonance imaging (MRI), 389
- pregnant patients, 409
- major adverse cardiac events (MACE), 26
- mandatory minute ventilation (MMV), 145
- manual hyperinflation (MHI), 169
- manual insufflation exsufflation, 170
- mass spectrometry, 42
- Maze procedure, 320
- mean arterial pressure (MAP), 263  
 phenylephrine effect, 127  
 target, 224
- mean frontal axis, 11
- mechanical chest compression devices (MCCDs), 226
- mechanical circulatory support (MCS),  
 173, 180. *See also* ventricular assist  
 devices (VAD)  
 contraindications and complications, 183  
 device comparisons, 176  
 device infections, 101–2  
 heart transplant patients, 335  
 Impella device, 175–76  
 intra-aortic balloon pump  
 (IABP), 173–75  
 out-of-hospital arrest management, 225,  
 226–27  
 paediatric, 423–24  
 TandemHeart device, 176  
 temporary, 180–81

- CentriMag system, 181  
 indications, 180–81  
 types of, 181
- mechanical ventilation, 142. *See also*  
 weaning from mechanical ventilation
- acute respiratory failure, 253  
 cardiac ECMO patients, 198  
 heart transplant patients, 334  
 modes, 143, 144–45
- airway pressure release ventilation (APRV), 145  
 assist-control ventilation (AC), 145  
 biphasic positive airway pressure (BIPAP), 145  
 continuous mandatory ventilation (CMV), 144  
 continuous positive airway pressure (CPAP), 145  
 intermittent positive pressure ventilation (IPPV), 169  
 mandatory minute ventilation (MMV), 145  
 pressure support ventilation (PSV), 145  
 selection of, 144  
 synchronised intermittent mandatory ventilation (SIMV), 145
- physiology, 147–48  
 cardiovascular effects, 147  
 respiratory effects, 147–48
- principles, 143–44  
 pressure control ventilation, 144  
 pressure regulated volume controlled ventilation (PRVC), 143  
 volume control ventilation, 143
- prolonged. *See* weaning from mechanical ventilation
- protective ventilation, 147
- pulmonary endarterectomy patients, 328
- special modalities, 145–47  
 differential ventilation, 146–47  
 high frequency ventilation (HFV), 146  
 inverted ratio ventilation (IRV), 145  
 neurally adjusted ventilatory assist (NAVA), 146  
 non-invasive ventilation (NIV), 147
- technical aspects, 142  
 cycling phase, 142  
 limiting phase, 142  
 triggering phase, 142
- variables, 143  
 expiration, 143  
 inspiration, 143
- ventilator hyperinflation (VHI), 170  
 weaning from. *See* weaning from mechanical ventilation
- medical emergency teams (MET), 216  
 medical negligence, 460  
 Mental Capacity Act, 2005, 457  
 mesenchymal stem cells (MSCs), 369
- mesenteric ischaemia, 296  
 metabolisable energy, 157, 158  
 methylene blue, 128  
 methylprednisolone, 336  
 microarray technology, 42  
 microbiological testing, 38  
 antibiotic susceptibility testing, 41  
 liaison with infection specialists, 42  
 microscopy and culture, 40–41  
 new technologies, 41  
 mass spectrometry, 42  
 microarrays, 42  
 molecular testing, 41  
 sequencing, 42  
 ordering tests, 38  
 results interpretation, 42  
 sampling procedures, 38–40  
 screening for resistant organisms, 40  
 surgical samples, 40  
 therapeutic drug monitoring, 41
- microcirculation, 256  
 midazolam, 133  
 milrinone, 125–26, 377
- mitral regurgitation, 318, 319  
 combined valvular pathologies, 321
- mitral stenosis, 318, 319, 320
- mitral valve, 319  
 calcification, 319  
 repair, 321  
 systolic anterior motion (SAM), 321
- mitral valve surgery, 318–20  
 anatomical considerations, 318–19  
 common ICU problems, 320  
 atrial fibrillation, 320  
 left ventricular dysfunction, 320  
 right ventricular dysfunction, 320  
 ventilatory failure, 320
- physiological considerations, 319–20
- mobilisation, 167–68  
 lung transplant patients, 344–45
- modelling. *See* risk models
- molecular testing, 41  
 morphine, 136  
 MRSA screening, 40  
 mTOR inhibitors, 337
- multidisciplinary teams, 445–46  
 multidrug resistant organisms (MDR), 103
- Multiplate platelet function assay, 114
- Mustard/Senning procedure, 431
- mycophenolate mofetil (MMF), 336
- myocardial infarction  
 CABG patients, 314  
 chest pain, 242–43  
 post percutaneous coronary intervention, 242  
 postsurgical revascularisation, 242–43  
 following thoracic surgery, 363  
 imaging studies, 45
- myocardial rupture, 244  
 myocarditis, 244
- myoclonic status epilepticus (MSE), 290  
 myoclonus, 290
- nasogastric feeds. *See* enteral nutrition
- neck examination, 4–5  
 negligence, 460
- neonates. *See also* congenital heart disease;  
 paediatrics  
 arrhythmias, 420  
 cardiogenic shock, 419  
 cyanosis, 418  
 management, 419  
 pulmonary oedema, 420
- nerve injuries in chest drainage, 74
- nesiritide, heart failure management, 376
- neurally adjusted ventilatory assist (NAVA), 146
- neurological complications, 380  
 brachial plexus injury, 383  
 cardiopulmonary bypass, 380–81  
 risk reduction, 381  
 cognitive decline, 385  
 considerations with cardiac surgery, 380  
 encephalopathy, 382–83  
 failure to awaken management, 388–89  
 clinical assessment, 388  
 neuroimaging, 389  
 neurophysiologic investigations, 389
- optic neuropathies, 383
- peripheral nervous system, 383–85  
 prevention, 388  
 stroke, 381–82  
 transplantation related  
 complications, 385–87
- neuromuscular blockade, 140
- neutrophils, 367
- nitrate, heart failure management, 376
- nitric oxide, 276, 422
- non-convulsive seizures (NCS), 285, 290  
 non-convulsive status epilepticus (NCSE), 285, 290, 383
- non-invasive ventilation (NIV), 147, 170  
*See also* ventilation  
 acute respiratory failure, 253  
 heart failure management, 375  
 role in difficult weaning from mechanical ventilation, 435–36  
 weaning failure, 438–39
- non-malefeasance, 456
- norepinephrine, 124, 275, 377
- nursing team, 441–43  
 advanced nursing roles, 443  
 bedside nurse, 441–42  
 education team, 441  
 health care support worker, 442  
 hierarchy, 442  
 lead nurse, 442  
 matron, 442  
 nurse manager, 442  
 shift leader, 443

## Index

- nutritional assessment, 157  
 nutritional requirements, 157–59  
   energy balance, 157  
   energy expenditure, 158  
   energy intake, 157  
   in disease, 159–60
- obstructive shock, 256
- oedema, 5
- oesophageal injury, 305  
   perforation, 297  
     in chest drainage, 75
- oesophageal rupture, 245
- openness, 447
- opioids analgesia, 136–37
- optic neuropathies, 383
- organ donation, 227–28, 459  
   donation after brain death, 459  
   donation after circulatory death, 459  
   ECMO patients, 460
- orotracheal intubation. *See* intubation
- outcome measures, 166–67
- outreach, 443
- oxycodone, 136
- oxygen therapy, acute respiratory  
   failure, 253
- P wave, 9
- pacing  
   complications, 80  
   implant complications, 80  
   implantable cardioverter defibrillators  
     (ICDs), 79  
   pacemaker functioning, 78  
   pacemaker magnet mode, 82  
   pacemaker types, 79  
   pacing mode, 78–79  
   pacing threshold, 78  
   troubleshooting, 81–82  
   when to pace, 78
- paediatrics  
   circulation assessment, 418  
   complications, 424–25  
     acute kidney injury, 425  
     arrhythmias, 424  
     cardiac tamponade, 424  
     chylothorax, 425  
     neurological complications, 425  
     phrenic nerve injury, 425  
     residual lesions, 424  
   congenital heart disease, 418–22  
     presentations, 418–20  
     mechanical circulatory support, 423–24  
   postoperative care following cardiac  
     surgery, 420–22  
   pulmonary circulation and  
     hypertension, 422  
   tamponade, 422  
   univentricular circulations, 422
- pain, 135. *See also* analgesia; chest pain
- pancreatitis, 296–97
- parenteral nutrition, 161–62
- patient preparation  
   bronchoscopy, 32  
   chest drainage, 71  
   intubation, 60
- penetrating injuries. *See* trauma
- peptic ulcer, 295  
   perforated, 298
- percussion, 168
- percutaneous coronary intervention (PCI)  
   recommendations, 224
- pericardial tamponade, 4  
   imaging studies, 48
- pericarditis, 244
- pericardium, echocardiography, 17–18
- peripartum cardiomyopathy, 408, 413
- peritoneal dialysis, 149
- phenylephrine, 127–28, 275
- phenytoin, 291
- phosphodiesterase (PDE) inhibitors, 377
- phrenic nerve, 383  
   injury, 425
- physical examination. *See* examination
- physical functional intensive care test  
   (PFIT), 166
- physiotherapy. *See* rehabilitation;  
   respiratory physiotherapy
- PiCCO system, 91–92
- pimobendan, 126
- plasmin, 309
- platelets, 108–10, 309  
   inherited platelet disorders, 403
- pleural drainage. *See* chest drainage
- pleural effusion, 70  
   chylous effusion, 425  
   imaging studies, 51  
   ultrasound assessment, 44
- pleural space, 70
- pneumonia, 252  
   community acquired, 252  
   following thoracic surgery, 361  
   imaging studies, 53  
   interstitial, 53  
   lobar, 53  
   ventilator associated (VAP), 147,  
     281–82  
     diagnosis, 29–30  
     reduction strategies, 281
- pneumothorax, 70, 244, 250–51, 360  
   imaging studies, 51  
   spontaneous, 250  
   treatment, 251
- positive end expiratory pressure  
   (PEEP), 144  
   ARDS patients, 368
- postcardiac arrest brain injury, 458–59
- postcardiac arrest myocardial  
   dysfunction, 221
- postcardiac arrest syndrome, 220–21
- postoperative pulmonary complications  
   (PPCs), 167. *See also* respiratory  
   physiotherapy
- post-transplantation lymphoproliferative  
   disorder (PTLD), 387
- PR interval, 9
- praecordium examination, 5
- precordial electrodes, 7
- pre-eclampsia, 410  
   diagnosis, 410  
   severe pre-eclampsia, 411
- pregnancy, 408  
   amniotic fluid embolism, 413  
   arrhythmias, 415  
   cardiopulmonary bypass, 415  
   cardiovascular changes, 408–9  
   congenital heart disease, 413–14  
   coronary artery disease, 414–15  
   counselling and genetic testing, 415  
   CVD diagnosis, 409–10  
     history and examination, 409  
   deep vein thrombosis, 415  
   hypertensive disorders, 410–12  
     postpartum care, 412  
   hypertrophic cardiomyopathy, 413  
   labour management, 414  
   peripartum cardiomyopathy, 413
- prehydration, coronary angiography, 23
- premedication, coronary angiography, 23
- preoxygenation, 61
- pressure control ventilation, 144
- pressure monitoring, 86–87  
   central pressures, 89  
   damping, 87  
   resonance, 87  
   transducers, 86–87  
   zeroing, 87
- pressure regulated volume controlled  
   ventilation (PRVC), 143
- pressure support ventilation (PSV), 145
- preterm labour, 414
- primary graft dysfunction (PGD), 206,  
   340–41
- procalcitonin (PCT), 278
- prognosis, xxiii. *See also* risk models
- proliferation inhibitors, 336
- prone positioning, 253, 370
- propofol, 134
- propofol infusion syndrome (PRIS), 134
- prostacyclin, 276
- prosthetic valve endocarditis, 99
- protamine, 310
- protein, 160
- prothrombin complex, 110, 114
- protocols, 445
- pseudo-obstruction, 297
- publication issues, 461
- pulmonary artery catheter, 89–91  
   cardiac output monitoring, 90–91  
   components, 90

- evidence base, 91  
 heart failure monitoring, 374  
 historical background, 89  
 indications, 90  
 insertion, 90  
 measurements, 90  
 pulmonary capillary wedge pressure (PCWP), 272  
 pulmonary contusions, 54  
 pulmonary embolism, 19  
   ECMO applications, 206  
 imaging studies, 48  
 pulmonary endarterectomy (PEA), 273, 324, 326  
   complications, 329–30  
     pulmonary haemorrhage, 330  
     reperfusion lung injury, 329  
     right ventricular failure, 329–30  
 critical care management, 326–27  
   cerebrovascular issues, 329  
   drugs, 328  
   fluid balance, 329  
   haematology, 329  
   monitoring, 327–28  
   ventilation, 328  
 operative principles, 326  
 outcomes, 330  
 patient selection, 326  
 surgical techniques, 326  
 pulmonary haemorrhage, 330  
 pulmonary hypertension, 272–73, 325  
   *See also* chronic thromboembolic pulmonary hypertension (CTEPH)  
 aetiology, 273  
 diagnosis, 325  
 ECMO support, 206, 207  
 lung transplantation, 343  
 medical therapy, 275–76  
   catecholamines, 275  
   dobutamine, 275  
   levosimendan, 275  
   pulmonary vasodilators, 276  
   vasopressin, 275  
   vasopressors, 275  
 monitoring, 274  
 paediatric, 422  
 resuscitation, 274–75  
 supportive care, 273  
 treatment of underlying causes, 273  
 pulmonary oedema, 251–52, 253, 372  
   *See also* chest drainage  
   imaging studies, 47  
   neonatal, 420  
   re-expansion, 74  
 pulmonary thromboendarterectomy (PTE), 207  
 pulmonary torsion, 54  
 pulmonary vascular disease, ECMO applications, 206–7  
 pulse pressure variation, 88  
 QRS axis estimation, 11  
 QRS complex, 9  
 QRS transition, 11  
 QT interval, 9  
 radial artery, post procedural care, 24  
 Rastelli procedure, 431  
 recombinant activated factor VIIa, 111, 311  
 recruitment manoeuvres, 368  
 recurrent laryngeal nerve, 384  
 red blood cells, 107–8  
 regional analgesia, 139–40  
 regional wall motion abnormalities (RWMA), 16, 17  
 rehabilitation  
   adjuncts and treatment, 165–66  
   aims, 164–65  
   barriers, 167  
   early, 165  
   outcome measures, 166–67  
   practicalities and safety issues, 166  
 remifentanyl, 137  
 renal dysfunction, xxiv  
 renal replacement therapy (RRT), 149  
   anticoagulation, 153–54  
   discontinuation, 154  
   dose, 152–53  
   indications, 149, 151–52  
   monitoring, 154  
   nutritional implications, 162  
   outcome, 154  
   timing, 151  
   types of, 149–51  
 reperfusion lung injury, 329  
 reperfusion response, 222  
 research and development, 448  
   ethical and legal issues, 460  
   consent, 461  
   publication issues, 461  
 resonance, 87  
 respiratory distress, 4  
 respiratory muscle training, 171  
 respiratory physiotherapy, 167–70  
   active cycle of breathing technique (ACBT), 168  
   breathing exercises, 168  
   cardiac patients, 171  
   ECMO patients, 171  
   incentive spirometry, 168  
   indications, 167  
   intermittent positive pressure ventilation (IPPV), 169  
   manual hyperinflation (MHI), 169  
   manual insufflation/exsufflation, 170  
   manual techniques, 168  
   mobilisation, 167–68  
   positioning, 168  
   respiratory muscle training, 171  
   thoracic surgery patients, 171  
   ventilator hyperinflation (VHI), 170  
 respiratory quotient (RQ), 159  
 resting metabolic rate, 158  
 restrictive cardiomyopathy, 18  
 restrictive fluid strategy, 254  
 resuscitation. *See also* advanced life support (ALS); basic life support (BLS)  
   catheter laboratory arrests, 218  
   general ward, 215–18  
   guidelines, 211  
   incidence, 211  
   late resuscitation, 215  
 rib fractures, 302  
 Richmond Agitation-Sedation Scale (RASS), 131, 397  
 right axis deviation, 12  
 right bundle branch block (RBBB), 12  
 right coronary artery (RCA), 24  
 right dominant circulation, 24  
 right ventricle (RV) echocardiography, 17  
 right ventricular assist device (RVAD), 180, 188  
 right ventricular dysfunction  
   grown-up congenital heart disease, 429  
   heart transplant patients, 335  
   treatment, 335  
 right ventricular failure, 17, 188  
   following thoracic surgery, 363  
   imaging studies, 48  
   mitral valve surgery patients, 320  
   pulmonary endarterectomy patients, 329–30  
 right ventricular index of myocardial performance (RIMP), 184  
 risk factors  
   postoperative, xxv  
     circulatory, xxv  
     gastrointestinal/hepatic, xxv  
     neurological, xxv  
     renal, xxv  
     respiratory, xxv  
   preoperative, xxiv–xxv  
     age, xxiv  
     disease extent, xxiv  
     gender, xxiv  
     left ventricular function, xxiv  
     lung disease, xxiv  
     previous surgery, xxiv  
     renal disease, xxiv  
     type of surgery, xxiv  
 risk management, 447  
 risk models, xxiii–xxv  
   postoperative, xxiii, xxv  
   risk factors, xxv  
   preoperative, xxiii–xxv  
   risk factors, xxiv–xxv  
   thoracic surgery, xxv  
 rocuronium, 60  
 saline solution, 119  
 sampling procedures, 38–40

## Index

- scoring systems, xxiii. *See also* risk models
- sedation, 130–31  
 alpha<sub>2</sub>-adrenoceptor agonists, 134  
 benzodiazepines, 133–34  
 bronchoscopy, 34  
 clonidine, 134  
 dexmedetomidine, 135  
 infusion pharmacokinetics, 130  
 monitoring, 131  
 planning, 131–33  
 propofol, 134
- Sedation-Agitation Scale (SAS), 131
- seizures, 285  
 burden of, 285–86  
 causes and prognostic  
 significance, 288–90  
 post cardiac arrest, 290  
 post cardiac surgery, 288–90  
 diagnosis, 285  
 general intensive care  
 considerations, 290–91  
 management, 291–92  
 paediatric, 425  
 prophylaxis with pre-eclampsia, 412  
 transplant patients, 387  
 versus epileptiform activity, 292
- selective antegrade cerebral perfusion (SACP), 351
- selective digestive decontamination (SDD), 281
- sepsis, 290. *See also* infections  
 definition, 278  
 general clinical management, 279–80  
 identification, 278  
 ventricular assist device  
 complications, 188
- septic shock, 256
- sequencing technologies, 42
- sequential organ failure score (SOFA), 278
- serotonin release assay (SRA), 405
- serum creatinine. *See* creatinine levels
- shivering, hypothermia response, 226
- shock  
 cardiogenic. *See* cardiogenic shock  
 definition, 256  
 diagnosis, 257–58  
 distributive, 256  
 epidemiology, 257  
 hypovolaemic, 256  
 monitoring, 258–60  
 ECG, 259–60  
 fluid responsiveness, 258–59  
 obstructive, 256  
 pathophysiology, 256–57  
 septic, 256  
 therapeutic strategies, 260–61
- shunt  
 intracardiac, 249  
 intrapulmonary, 249
- sildenafil, 276
- single lung ventilation, 146–47
- sirolimus, 337
- SOFA score, xxv
- somatosensory evoked potentials (SSEPs), 389
- spinal cord drainage, 352–53
- sputum samples, 40
- ST segment, 9
- standardised mortality ratio (SMR), 447
- status epilepticus, 285  
 myoclonic (MSE), 290
- stem cell therapies, 369
- sternal closure, delayed, 422
- sternal dehiscence, 245
- steroid therapy, 369
- stool samples, 39
- stroke, 381–82  
 aortic stenosis patients, 318  
 risk factors, 388  
 ventricular assist device  
 complications, 188
- subclavian cannulation, 196
- suctioning, 170, 281
- superior cavopulmonary connection, 423
- superior vena cava (SVC), 20
- superior vena cava syndrome (SVCS), 243
- supraventricular arrhythmias, 12–13
- surgical samples, 40
- surgical site infections, 282–83  
 management, 283  
 prevention strategies, 283
- Surviving Sepsis Campaign, 279
- suxamethonium, 60
- swallowing, with tracheostomy, 66
- synchronised intermittent mandatory ventilation (SIMV), 145
- Syntax score, xxiv
- systemic inflammatory response syndrome (SIRS), 222
- systemic vascular resistance (SVR), 123, 258
- systemic-pulmonary shunt, 431
- systolic anterior motion (SAM), 321  
 management, 321  
 predisposing factors, 321
- T wave, 9
- tachyarrhythmias, 12–13  
 heart transplant patients, 334  
 paediatric, 420  
 cardiac surgery complications, 424  
 supraventricular, 12–13  
 ventricular, 13
- tacrolimus, 337  
 side effects, 387
- Takotsubo cardiomyopathy, 245
- tamponade. *See* cardiac tamponade
- TandemHeart device, 176
- targeted temperature management (TTM), 225–26  
 physiological responses, 226
- tension pneumothorax, 74, 244
- tetralogy of Fallot, 431
- thoracic aortic aneurysm (TAA), 348–49  
 endovascular stent graft, 349  
 medical management, 349  
 open surgery, 348–49
- thoracic endovascular aortic repair (TEVAR), 353. *See also* aortic surgery
- thoracic expansion exercises (TEEs), 168
- thoracic injury. *See* trauma
- thoracic surgery, 356. *See also* aortic surgery  
 complications, 363  
 acute respiratory distress  
 syndrome, 359–60  
 air leak and pneumothorax, 360  
 atelectasis, 361  
 bleeding, 363  
 bronchopleural fistula, 360–61  
 cardiac dysfunction, 361–63  
 infections, 361  
 mortality, 356  
 reduction of mortality and  
 complications, 356–59  
 analgesia, 357–59  
 enhanced recovery, 357  
 pleural drainage, 357  
 thromboprophylaxis, 359  
 video assisted thoracic surgery (VATS), 356  
 risk modelling, xxv
- thoracotomy, 357  
 indications, 304  
 pain control, 344
- Thoratec HeartMate 3, 182
- thrombocytopenia, 111
- thromboelastography (TEG), 114
- thromboprophylaxis, 359
- thrombosis  
 deep venous, 5, 415  
 ventricular assist device  
 complications, 188
- total cavopulmonary connection, 423
- tracheobronchial injuries, 303
- tracheobronchial tears, 54
- tracheoinnominate artery fistula, 237
- tracheostomy, 64–66, 233  
 advantages, 64  
 bronchoscopy and, 34  
 complications, 237  
 decannulation, 66  
 emergencies, 235–37  
 airway bleeding, 237  
 blocked tube, 237  
 dislodgement, 237

- indications, 64
  - insertion technique, 65
    - percutaneous, 65
    - surgical, 65
  - management, 66
  - percutaneous, 233
  - swallowing and, 66
  - timing, 65–66
  - tubes, 64–65
    - cuffed and uncuffed, 64
    - fenestrated and non-fenestrated, 65
    - single and double cannula, 65
  - weaning protocol, 66
  - training
    - current status, 463–64
    - echocardiography, 465
    - future of, 465
    - historical background, 463
    - opportunities, 464–65
  - tramadol, 139
  - tranexamic acid (TXA), 290, 309–10
  - transducers, 86–87
    - zeroing, 87
  - transposition of the great arteries, 431
    - congenitally corrected, 431
  - transpulmonary dilution and pulse contour analysis, 91–92
    - LiDCO system, 92
    - non-calibrated systems, 92
    - PiCCO system, 91–92
  - transpulmonary gradient (TPG), 185
  - trauma, 301
    - aortic injury, 304–5
    - bronchoscopy indications, 30–31
    - cardiac injuries, 304
    - cardiothoracic trauma mechanisms, 301
    - chest wall, 302
    - clinical assessment, 301
    - desaturation, imaging studies, 54
    - diaphragmatic injury, 305
    - echocardiography indications, 19
    - imaging, 301–2
    - lung injuries, 303
    - oesophageal injury, 305
    - thoracic aorta, 349
    - tracheobronchial injuries, 303
  - tricuspid annular plane systolic excursion (TAPSE), 184
  - tricuspid regurgitation, 17, 185, 320
  - tricuspid valve, 320
    - surgery, 320–21
  - tropomyosin, 126
  - troponin C (TnC), 126
  - U wave, 9
  - ultraprotective ventilation, 205
  - ultrasound imaging, 44
  - univentricular circulation, 422
    - grown-up congenital heart disease, 429
    - initial palliation, 422
    - superior cavopulmonary connection, 423
    - total cavopulmonary connection, 423
  - urine samples, 40
  - valproate, 292
  - valve surgery patients, 317
    - aortic valve, 317–18
      - common ICU problems, 318
    - combined valvular pathologies, 321
    - implant considerations, 321
      - choice of prosthesis, 321
    - mitral valve, 318–20
      - common ICU problems, 320
    - postoperative anticoagulation, 321
    - tricuspid valve, 320–21
  - valvular heart disease,
    - echocardiography, 17
  - vascular access, 86
    - arterial catheters, 87–88
    - cardiac ECMO cannulation strategies, 194–96. *See also* cardiac ECMO
    - catheter insertion, 86
    - catheter related bloodstream infections, 100–1
    - central venous catheters, 88–89
    - complications, 86
      - pressure monitoring, 86–87
    - pulmonary artery catheter, 89–91
  - vascular air embolism, 243–44
  - vasoactive receptors, 123
  - vasodilators, 253, 276, 369
    - heart failure management, 375
  - vasopressin, 127, 213, 275
  - vasopressors, 275
  - venoarterial carbon dioxide difference (pCO<sub>2</sub> gap), 258
  - venoarterial ECMO, 202
  - venovenous ECMO, 202, 203
  - ventilation, 213–14. *See also* mechanical ventilation
    - ARDS patients, 368
      - protective ventilation, 368
    - ventilatory modes, 368
  - decreased tidal ventilation, 250
  - during bronchoscopy, 34
  - failed, 63
  - heart transplant patients, 334
  - out-of-hospital arrest management, 225
- ventilation and perfusion (V/Q) mismatch, 248–49
- ventilator associated lung injury (VALI), 147
  - acute respiratory distress syndrome, 367
  - burden of, 368
- ventilator associated pneumonia (VAP), 147, 281–82
- definition, 282
- diagnosis, 29–30
  - reduction strategies, 281
- ventilator hyperinflation (VHI), 170
- ventricular arrhythmias, 13
- ventricular assist devices (VAD), 180
  - See also* mechanical circulatory support (MCS)
- complications, 187–89
  - aortic regurgitation, 189
  - device failure, 189
  - infections, 102, 188
  - neurological complications, 188
  - postoperative bleeding, 187
  - right heart failure, 187–88
  - thrombosis, 188
- components, 180
- Impella, 175–76
- implantable/durable devices, 79
  - indications, 182
  - patient selection, 184
  - types of, 181–82
- implantation risk factor assessment, 184–85
  - cardiac factors, 184
  - ECG assessment, 184
- infection, 281
- outcome, 189
- perioperative management during implantation, 185–87
  - ICU and ward care, 186
  - preoperative planning, 185
  - VAD team, 186–87
- self care, 187
- ventricular fibrillation, pulseless, 212
- ventricular tachycardia (VT), pulseless, 212
- ventriculoarterial (VA) coupling, 257
- video assisted thoracic surgery (VATS), 356
- videolaryngoscopy, 62
- viral infections. *See also* infections
  - lung transplant patients, 342
- volume control ventilation, 143
- von Willebrand factor (vWF), 311
- von Willebrand's disease, 402–3
- warfarin, 32, 321, 329
- weaning from mechanical ventilation, 434
  - difficult weaning, 435
    - extubation delay, 435
    - non-invasive ventilation role, 435–36
    - role of checklists and prompts, 435
  - protocols for early extubation, 434
  - screening parameters for early extubation, 434
  - simple weaning, 434–35
  - weaning failure, 436–39
    - associated factors, 436–37
    - data from clinical studies, 439

**Index**

- weaning from mechanical ventilation (*cont.*)
  - environment normalisation, 438
  - gas exchange normalisation, 437
  - identification of causes, 437–38
  - impact of prolonged mechanical ventilation, 436
- multidisciplinary team approach, 438
- non-invasive ventilation role, 438–39
- specialised weaning unit role, 436
- trials of unsupported breathing, 438
- weaning to most appropriate level, 439
- Wilson's central terminus, 8
- withdrawing treatment, 458
- withholding treatment, 458
- Wolff–Parkinson–White syndrome (WPW), 13
- wound pain, 245
- wound swabs, 40
- written consent for coronary angiography, 23